Norland Q2 sales rebound over first quarter

Article

Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a

Bone densitometry manufacturer Norland Medical Systems saw its second-quarter revenues more than double compared with the first quarter of this year, but sales were still lower than in the second quarter of 1997. The White Plains, NY, company enjoyed a 135% second-quarter increase in revenue over first quarter of the year, with sales of $4.8 million. That figure, however, fell 6% short of the $5.1 million in sales that the company recorded in the second quarter of 1997.

Norland reported a net loss for the quarter of $1.5 million, compared with net income of $195,000 in the second quarter of 1997. Although revenues are still lower than last year's levels, the company said that sales are rebounding for both peripheral and axial dual-energy x-ray absorptiometer (DEXA) products. Norland also reported healthy demand for its new Apollo DXA peripheral scanner (SCAN 6/10/98), although that system was not released in time to contribute much to the company's second-quarter results. Norland executives say the firm has sold more Apollo systems since the product's introduction than any other of its peripheral units.

Norland's revenue rebound was overshadowed by a pending decision from the NASDAQ Stock Market's delisting hearing panel on the company's market eligibility. Norland has run afoul of the exchange's $4 million net tangible assets requirement. The company met with the delisting panel on July 29 and is awaiting a decision on its NASDAQ status.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.